AVEF.F Stock Overview
A biotechnology company, engages in the development and commercialization of human and animal health related products using its proprietary drug delivery system and Tocopherol Phosphate Mixture in Australia. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Avecho Biotechnology Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.0012 |
52 Week High | AU$0.003 |
52 Week Low | AU$0.0012 |
Beta | 2.12 |
11 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | 500.00% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -99.45% |
Recent News & Updates
Recent updates
Shareholder Returns
AVEF.F | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 0% | 1.6% | 2.2% |
1Y | 500.0% | 9.9% | 31.6% |
Return vs Industry: AVEF.F exceeded the US Pharmaceuticals industry which returned 9% over the past year.
Return vs Market: AVEF.F exceeded the US Market which returned 29.6% over the past year.
Price Volatility
AVEF.F volatility | |
---|---|
AVEF.F Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 9.5% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.7% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AVEF.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine AVEF.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1992 | n/a | Paul Gavin | avecho.com.au |
Avecho Biotechnology Limited, a biotechnology company, engages in the development and commercialization of human and animal health related products using its proprietary drug delivery system and Tocopherol Phosphate Mixture in Australia. The company operates through Production and Human Health segments. It also produces and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations.
Avecho Biotechnology Limited Fundamentals Summary
AVEF.F fundamental statistics | |
---|---|
Market cap | US$6.14m |
Earnings (TTM) | -US$2.25m |
Revenue (TTM) | US$219.06k |
28.0x
P/S Ratio-2.7x
P/E RatioIs AVEF.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AVEF.F income statement (TTM) | |
---|---|
Revenue | AU$339.30k |
Cost of Revenue | AU$494.03k |
Gross Profit | -AU$154.73k |
Other Expenses | AU$3.33m |
Earnings | -AU$3.48m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.0011 |
Gross Margin | -45.60% |
Net Profit Margin | -1,026.91% |
Debt/Equity Ratio | 0% |
How did AVEF.F perform over the long term?
See historical performance and comparison